NCT06515834View on ClinicalTrials.gov

Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Japanese Persons

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

November 28, 2024

Study Completion Date

November 28, 2024

Conditions
Gastroenterology
Interventions
DRUG

FE 999301

To assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men

DRUG

Placebo

Placebo to assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men

Trial Locations (1)

130-0004

Ferring Investigational Site, Sumida-Ku

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY